<DOC>
	<DOCNO>NCT01256567</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability anti-VEGFR-2 monoclonal antibody ramucirumab drug product combination docetaxel Japanese participant metastatic , locally advanced breast cancer , aim confirm recommend dose ramucirumab drug product ( DP ) combination docetaxel .</brief_summary>
	<brief_title>A Study Ramucirumab ( IMC-1121B ) Participants With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>The participant Japanese The participant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 The participant histopathologically cytologically confirm diagnosis breast adenocarcinoma metastatic locallyrecurrent inoperable curative intent The participant measurable and/or nonmeasurable disease The participant ' primary and/or metastatic tumor Human Epidermal Growth Factor Receptor 2 ( HER2 ) negative The participant receive neo adjuvant adjuvant taxane therapy ≥ 6 month prior study The participant receive neo adjuvant adjuvant biologic therapy ≥ 6 week prior study The participant complete prior radiotherapy ≥ 3 week prior study registration date The participant receive prior hormonal therapy breast cancer neo adjuvant , adjuvant , and/or metastatic setting ≥ 2 week prior study registration date The participant 's left ventricular ejection fraction ( LVEF ) within normal range The participant adequate hematologic , hepatic , coagulation function . Eligible participant reproductive potential agree use adequate contraceptive method ( hormonal barrier method ) study period 12 week last dose study medication The participant concurrent active malignancy breast adenocarcinoma , adequately treat nonmelanomatous skin cancer , noninvasive carcinoma situ neoplasm . Participants previous treatment malignancy eligible , provided disease free &gt; 3 year The participant know sensitivity docetaxel The participant know sensitivity agent similar biologic composition ramucirumab The participant history chronic diarrheal disease within 6 month prior study registration date The participant receive irradiation major bone marrow area within 30 day prior study registration date The participant receive experimental agent within 4 week prior study registration date The participant history uncontrolled hereditary acquire bleed thrombotic disorder The participant Grade 34 bleeding within 3 month prior study registration date The participant ongoing active infection require antibiotic , antifungal , antiviral therapy The participant uncontrolled hypertension , symptomatic congestive heart failure , psychiatric illness , serious uncontrolled medical disorder The participant brain metastases The participant know human immunodeficiency virus infection acquire immunodeficiency syndrome related illness The participant pregnant lactate The participant fully recover effect prior chemotherapy The participant undergone major surgery within 28 day prior study registration date</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>